Name: Clinica Synaptica
Price range: $

Neuroplasticity and ketamine: a new horizon in mental health

Depression, anxiety and chronic stress are associated with the loss and retraction of dendritic spines, disrupting communication between key brain regions involved in emotion, memory and decision-making. This disconnection reduces cognitive flexibility and promotes rumination and rigid negative patterns. Ketamine and other psychedelics have been shown to rapidly enhance neuroplasticity by increasing the formation and stabilization of dendritic spines, reopening critical learning periods. When combined with psychotherapy and supportive habits, this window of plasticity can facilitate lasting emotional and behavioral change.

...

Debora Gonzalez 12/11/2025

Ketamine for Treatment Resistant Depression: Real World Evidence

Treatment-resistant depression affects up to one third of patients with major depressive disorder and is linked to severe impairment and suicide risk. Real-world clinical data show that ketamine offers rapid antidepressant effects, with meaningful symptom reduction in nearly half of treated patients and remission in around one third. Benefits often appear within hours or days and can be maintained over time with follow-up treatment. Evidence also indicates good tolerability, low risk of symptom worsening and effectiveness in both unipolar and bipolar depression.

...

Debora Gonzalez 04/11/2025

Microdosing psychedelics: potential benefits and current evidence

Microdosing psychedelics involves taking sub-perceptual doses of substances such as psilocybin or LSD with the aim of improving mood, cognition and emotional wellbeing. This article reviews current scientific evidence on microdosing, including proposed neurobiological mechanisms, potential benefits for depression and anxiety, cognitive and motivational effects, safety considerations and the role of placebo. While observational studies suggest possible benefits, controlled trials show mixed results, highlighting important limitations and the need for further rigorous research before clear clinical recommendations can be made.

...

Marta Martín Islas 09/09/2025

Psilocybin and depression

Psilocybin-assisted therapy is emerging as a promising approach for depression, particularly treatment-resistant cases where standard antidepressants show limited efficacy and burdensome side effects. Research suggests psilocybin can produce rapid and sustained reductions in depressive symptoms, partly by enhancing neuroplasticity and facilitating meaningful psychological experiences. When embedded in a structured therapeutic model with preparation, dosing, and integration sessions, psilocybin may foster emotional openness, cognitive flexibility, and long-term positive change, highlighting a potential paradigm shift in how depression is treated within modern clinical research frameworks.

...

Òscar Parés Franquero 23/12/2024

When nothing else works: Ketamine for treatment-resistant depression

Treatment-resistant depression occurs when major depressive disorder does not respond to at least two adequate treatments, leading to prolonged suffering and functional impairment. Many patients fail to achieve full remission, despite multiple medication trials, increasing the risk of chronicity and hospitalization. Recent clinical evidence shows ketamine can produce rapid and meaningful symptom reduction in this population, including decreases in suicidal ideation and anxiety. Ongoing and maintenance ketamine sessions may further improve outcomes, offering new hope for patients who have not benefited from conventional antidepressant therapies

...

Marta Martín Islas 29/04/2024

Ketamine and depression: the first days of treatment

Depression is a complex disorder affecting mood, cognition, and physical health, and is the leading cause of disability worldwide. Standard treatment combines antidepressant medication and psychotherapy, yet around one third of patients do not respond adequately. This has driven interest in alternatives such as ketamine, a dissociative anesthetic with rapid antidepressant effects. Clinical trials and meta-analyses show symptom improvement within hours and remission in some patients. Ketamine is generally well tolerated and most effective when combined with psychotherapeutic support and careful medical supervision.

...

Marta Martín Islas 01/03/2024